33 results on '"Naamane N"'
Search Results
2. OP0012 INTERFERON-α MEDIATED THERAPEUTIC RESISTANCE IN EARLY RA IMPLICATES EPIGENETIC REPROGRAMMING
- Author
-
Cooles, F., primary, Tarn, J., additional, Lendrem, D., additional, Naamane, N., additional, Lin, A., additional, Millar, B., additional, Maney, N., additional, Thalayasingam, N., additional, Bondet, V., additional, Duffy, D., additional, Barnes, M., additional, Smith, G., additional, Ng, S., additional, Watson, D., additional, Henkin, R., additional, Cope, A., additional, Reynard, L., additional, Pratt, A., additional, Consortium, R. M., additional, and Isaacs, J., additional
- Published
- 2022
- Full Text
- View/download PDF
3. AB0021 CHARACTERISATION OF AGE-ASSOCIATED B CELLS IN EARLY, DRUG NAÏVE RHEUMATOID ARTHRITIS
- Author
-
Vidal-Pedrola, G., primary, Naamane, N., additional, Scheel-Toellner, D., additional, Pratt, A., additional, Mellor, A., additional, Isaacs, J. D., additional, and Anderson, A. E., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation
- Author
-
Gurzov, E N, Barthson, J, Marhfour, I, Ortis, F, Naamane, N, Igoillo-Esteve, M, Gysemans, C, Mathieu, C, Kitajima, S, Marchetti, P, Ørntoft, T F, Bakiri, L, Wagner, E F, and Eizirik, D L
- Published
- 2012
- Full Text
- View/download PDF
5. Induction of nuclear factor-κB and its downstream genes by TNF-α and IL-1β has a pro-apoptotic role in pancreatic beta cells
- Author
-
Ortis, F., Pirot, P., Naamane, N., Kreins, A. Y., Rasschaert, J., Moore, F., Théâtre, E., Verhaeghe, C., Magnusson, N. E., Chariot, A., Ørntoft, T. F., and Eizirik, D. L.
- Published
- 2008
- Full Text
- View/download PDF
6. THU0005 VARIABILITY OF DNA METHYLATION IS A DRIVER OF LYMPHOCYTE DYSREGULATION IN EARLY RHEUMATOID ARTHRITIS.
- Author
-
Clark, A., primary, Naamane, N., additional, Nair, N., additional, Anderson, A., additional, Thalayasingam, N., additional, Diboll, J., additional, Barton, A., additional, Eyre, S., additional, Isaacs, J. D., additional, Reynard, L., additional, and Pratt, A., additional
- Published
- 2020
- Full Text
- View/download PDF
7. IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function
- Author
-
Ridgley, LA, Anderson, AE, Maney, NJ, Naamane, N, Skelton, AJ, Lawson, CA, Emery, P, Isaacs, JD, Carmody, RJ, and Pratt, AG
- Abstract
Objective: We have previously shown that increased circulating interleukin-6 (IL-6) results in enhanced CD4+ T cell signaling via signal transduction and activator of transcription-3 (STAT3) in early rheumatoid arthritis (RA). We tested the hypothesis that transcriptional “imprinting” of T-cells by this mechanism skews downstream effector responses, reinforcing immune dysregulation at a critical, but targetable, disease phase. Methods: We modeled naïve CD4+ T cell exposure to pathophysiological concentrations of IL-6 in vitro, assessing the dynamic transcriptional and functional consequences for downstream effector cells utilizing microarray and flow cytometry. Fresh blood from treatment-naïve early arthritis patients was phenotyped in parallel for comparison. Results: T cell sensitivity to IL-6 was most marked in the naïve subset, and related to gp130 rather than IL-6R expression. Exposure of healthy naïve CD4+ T cells to IL-6 induced the same STAT3 target genes as previously seen to discriminate RA patients from disease controls. After TCR stimulation IL-6 pre-exposed cells exhibited enhanced proliferative capacity, activation, and a propensity toward Th1 differentiation, compared to non-exposed cells. An entirely analogous phenotype was observed in early RA compared to control CD4+ T cells. Conclusions: Sustained IL-6 exposure at a critical point in the natural history of RA “primes” the adaptive immune system to respond aberrantly to TCR stimulation, potentiating disease induction with implications for the optimal timing of targeted therapy.
- Published
- 2019
8. P106/O25 DNA methylation in lymphocyte subsets as a mediator of genetic risk in early rheumatoid arthritis
- Author
-
Clark, AD, primary, Nair, N, additional, Skelton, AJ, additional, Anderson, AE, additional, Thalayasingam, N, additional, Naamane, N, additional, Diboll, J, additional, Massey, J, additional, Eyre, S, additional, Barton, A, additional, Isaacs, JD, additional, Reynard, LN, additional, and Pratt, AG, additional
- Published
- 2019
- Full Text
- View/download PDF
9. P124 Altered CD4+ T cell DNA methylation in early rheumatoid arthritis
- Author
-
Clark, AD, primary, Naamane, N, additional, Nair, N, additional, Anderson, AE, additional, Skelton, AJ, additional, Diboll, J, additional, Massey, J, additional, Eyre, S, additional, Barton, A, additional, Isaacs, JD, additional, Reynard, LN, additional, and Pratt, AG, additional
- Published
- 2018
- Full Text
- View/download PDF
10. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients
- Author
-
Volkmar, M, Dedeurwaerder, S, Cunha, Da, Ndlovu, Mn, Defrance, M, Deplus, R, Calonne, E, Volkmar, U, Igoillo Esteve, M, Naamane, N, DEL GUERRA, Silvia, Masini, Matilde, Bugliani, Marco, Marchetti, Piero, Cnop, M, Eizirik, Dl, and Fuks, F.
- Subjects
endocrine system ,DNA methylation ,pancreatic islets ,Transcription, Genetic ,endocrine system diseases ,DNA Fingerprinting ,Article ,Sciences biomédicales ,Cell Line ,Epigenesis, Genetic ,Rats ,Islets of Langerhans ,Glucose ,Diabetes Mellitus, Type 2 ,Genetic Loci ,Animals ,Humans ,CpG Islands ,type 2 diabetes ,Promoter Regions, Genetic ,Biologie ,Aged - Abstract
In addition to genetic predisposition, environmental and lifestyle factors contribute to the pathogenesis of type 2 diabetes (T2D). Epigenetic changes may provide the link for translating environmental exposures into pathological mechanisms. In this study, we performed the first comprehensive DNA methylation profiling in pancreatic islets from T2D and non-diabetic donors. We uncovered 276 CpG loci affiliated to promoters of 254 genes displaying significant differential DNA methylation in diabetic islets. These methylation changes were not present in blood cells from T2D individuals nor were they experimentally induced in non-diabetic islets by exposure to high glucose. For a subgroup of the differentially methylated genes, concordant transcriptional changes were present. Functional annotation of the aberrantly methylated genes and RNAi experiments highlighted pathways implicated in β-cell survival and function; some are implicated in cellular dysfunction while others facilitate adaptation to stressors. Together, our findings offer new insights into the intricate mechanisms of T2D pathogenesis, underscore the important involvement of epigenetic dysregulation in diabetic islets and may advance our understanding of T2D aetiology. © 2012 European Molecular Biology Organization., SCOPUS: ar.j, FLWOA, info:eu-repo/semantics/published
- Published
- 2012
- Full Text
- View/download PDF
11. JunB protects β-cells from lipotoxicity via the XBP1–AKT pathway
- Author
-
Cunha, D A, primary, Gurzov, E N, additional, Naamane, N, additional, Ortis, F, additional, Cardozo, A K, additional, Bugliani, M, additional, Marchetti, P, additional, Eizirik, D L, additional, and Cnop, M, additional
- Published
- 2014
- Full Text
- View/download PDF
12. Unraveling the effects of 1,25(OH)2D3 on global gene expression in pancreatic islets
- Author
-
Wolden-Kirk, H., primary, Overbergh, L., additional, Gysemans, C., additional, Brusgaard, K., additional, Naamane, N., additional, Van Lommel, L., additional, Schuit, F., additional, Eizirik, D.L., additional, Christesen, H., additional, and Mathieu, C., additional
- Published
- 2013
- Full Text
- View/download PDF
13. Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation
- Author
-
Gurzov, E N, primary, Barthson, J, additional, Marhfour, I, additional, Ortis, F, additional, Naamane, N, additional, Igoillo-Esteve, M, additional, Gysemans, C, additional, Mathieu, C, additional, Kitajima, S, additional, Marchetti, P, additional, Ørntoft, T F, additional, Bakiri, L, additional, Wagner, E F, additional, and Eizirik, D L, additional
- Published
- 2011
- Full Text
- View/download PDF
14. EuroDia: a beta-cell gene expression resource
- Author
-
Liechti, R., primary, Csardi, G., additional, Bergmann, S., additional, Schutz, F., additional, Sengstag, T., additional, Boj, S. F., additional, Servitja, J.-M., additional, Ferrer, J., additional, Van Lommel, L., additional, Schuit, F., additional, Klinger, S., additional, Thorens, B., additional, Naamane, N., additional, Eizirik, D. L., additional, Marselli, L., additional, Bugliani, M., additional, Marchetti, P., additional, Lucas, S., additional, Holm, C., additional, Jongeneel, C. V., additional, and Xenarios, I., additional
- Published
- 2010
- Full Text
- View/download PDF
15. Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs
- Author
-
Pirot, P., primary, Naamane, N., additional, Libert, F., additional, Magnusson, N. E., additional, Ørntoft, T. F., additional, Cardozo, A. K., additional, and Eizirik, D. L., additional
- Published
- 2007
- Full Text
- View/download PDF
16. Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis.
- Author
-
Cunha DA, Igoillo-Esteve M, Gurzov EN, Germano CM, Naamane N, Marhfour I, Fukaya M, Vanderwinden JM, Gysemans C, Mathieu C, Marselli L, Marchetti P, Harding HP, Ron D, Eizirik DL, Cnop M, Cunha, Daniel A, Igoillo-Esteve, Mariana, Gurzov, Esteban N, and Germano, Carla M
- Abstract
Environmental factors such as diets rich in saturated fats contribute to dysfunction and death of pancreatic β-cells in diabetes. Endoplasmic reticulum (ER) stress is elicited in β-cells by saturated fatty acids. Here we show that palmitate-induced β-cell apoptosis is mediated by the intrinsic mitochondrial pathway. By microarray analysis, we identified a palmitate-triggered ER stress gene expression signature and the induction of the BH3-only proteins death protein 5 (DP5) and p53-upregulated modulator of apoptosis (PUMA). Knockdown of either protein reduced cytochrome c release, caspase-3 activation, and apoptosis in rat and human β-cells. DP5 induction depends on inositol-requiring enzyme 1 (IRE1)-dependent c-Jun NH₂-terminal kinase and PKR-like ER kinase (PERK)-induced activating transcription factor (ATF3) binding to its promoter. PUMA expression is also PERK/ATF3-dependent, through tribbles 3 (TRB3)-regulated AKT inhibition and FoxO3a activation. DP5(-/-) mice are protected from high fat diet-induced loss of glucose tolerance and have twofold greater pancreatic β-cell mass. This study elucidates the crosstalk between lipotoxic ER stress and the mitochondrial pathway of apoptosis that causes β-cell death in diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells.
- Author
-
Ortis F, Naamane N, Flamez D, Ladrière L, Moore F, Cunha DA, Colli ML, Thykjaer T, Thorsen K, Orntoft TF, Eizirik DL, Ortis, Fernanda, Naamane, Najib, Flamez, Daisy, Ladrière, Laurence, Moore, Fabrice, Cunha, Daniel A, Colli, Maikel L, Thykjaer, Thomas, and Thorsen, Kasper
- Abstract
Objective: Cytokines contribute to pancreatic beta-cell death in type 1 diabetes. This effect is mediated by complex gene networks that remain to be characterized. We presently utilized array analysis to define the global expression pattern of genes, including spliced variants, modified by the cytokines interleukin (IL)-1beta + interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha + IFN-gamma in primary rat beta-cells.Research Design and Methods: Fluorescence-activated cell sorter-purified rat beta-cells were exposed to IL-1beta + IFN-gamma or TNF-alpha + IFN-gamma for 6 or 24 h, and global gene expression was analyzed by microarray. Key results were confirmed by RT-PCR, and small-interfering RNAs were used to investigate the mechanistic role of novel and relevant transcription factors identified by pathway analysis. RESULTS Nearly 16,000 transcripts were detected as present in beta-cells, with temporal differences in the number of genes modulated by IL-1beta + IFNgamma or TNF-alpha + IFN-gamma. These cytokine combinations induced differential expression of inflammatory response genes, which is related to differential induction of IFN regulatory factor-7. Both treatments decreased the expression of genes involved in the maintenance of beta-cell phenotype and growth/regeneration. Cytokines induced hypoxia-inducible factor-alpha, which in this context has a proapoptotic role. Cytokines also modified the expression of >20 genes involved in RNA splicing, and exon array analysis showed cytokine-induced changes in alternative splicing of >50% of the cytokine-modified genes.Conclusions: The present study doubles the number of known genes expressed in primary beta-cells, modified or not by cytokines, and indicates the biological role for several novel cytokine-modified pathways in beta-cells. It also shows that cytokines modify alternative splicing in beta-cells, opening a new avenue of research for the field. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
18. In silico identification of NF-kappaB-regulated genes in pancreatic beta-cells
- Author
-
Eizirik Decio L, van Helden Jacques, and Naamane Najib
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background Pancreatic beta-cells are the target of an autoimmune attack in type 1 diabetes mellitus (T1DM). This is mediated in part by cytokines, such as interleukin (IL)-1β and interferon (IFN)-γ. These cytokines modify the expression of hundreds of genes, leading to beta-cell dysfunction and death by apoptosis. Several of these cytokine-induced genes are potentially regulated by the IL-1β-activated transcription factor (TF) nuclear factor (NF)-κB, and previous studies by our group have shown that cytokine-induced NF-κB activation is pro-apoptotic in beta-cells. To identify NF-κB-regulated gene networks in beta-cells we presently used a discriminant analysis-based approach to predict NF-κB responding genes on the basis of putative regulatory elements. Results The performance of linear and quadratic discriminant analysis (LDA, QDA) in identifying NF-κB-responding genes was examined on a dataset of 240 positive and negative examples of NF-κB regulation, using stratified cross-validation with an internal leave-one-out cross-validation (LOOCV) loop for automated feature selection and noise reduction. LDA performed slightly better than QDA, achieving 61% sensitivity, 91% specificity and 87% positive predictive value, and allowing the identification of 231, 251 and 580 NF-κB putative target genes in insulin-producing INS-1E cells, primary rat beta-cells and human pancreatic islets, respectively. Predicted NF-κB targets had a significant enrichment in genes regulated by cytokines (IL-1β or IL-1β + IFN-γ) and double stranded RNA (dsRNA), as compared to genes not regulated by these NF-κB-dependent stimuli. We increased the confidence of the predictions by selecting only evolutionary stable genes, i.e. genes with homologs predicted as NF-κB targets in rat, mouse, human and chimpanzee. Conclusion The present in silico analysis allowed us to identify novel regulatory targets of NF-κB using a supervised classification method based on putative binding motifs. This provides new insights into the gene networks regulating cytokine-induced beta-cell dysfunction and death.
- Published
- 2007
- Full Text
- View/download PDF
19. Unraveling the effects of 1,25(OH)2D3 on global gene expression in pancreatic islets.
- Author
-
Wolden-Kirk, H., Overbergh, L., Gysemans, C., Brusgaard, K., Naamane, N., Van Lommel, L., Schuit, F., Eizirik, D.L., Christesen, H., and Mathieu, C.
- Subjects
- *
GENE expression , *ISLANDS of Langerhans , *VITAMIN D deficiency , *TYPE 1 diabetes , *TYPE 2 diabetes , *IN vitro studies - Abstract
Abstract: Introduction: Vitamin D deficiency has been linked to type 1 and 2 diabetes, whereas supplementation may prevent both diseases. However, the extent of the effects of vitamin D or its metabolites directly on pancreatic islets is still largely unknown. The aim of the present study was to investigate how active vitamin D, 1,25(OH)2D3, affects beta cells directly by establishing its effects on global gene expression in healthy murine islets. Materials and methods: Pancreatic islets were isolated from 2 to 3 week old C57BL/6 mice and cultured in vitro with 1,25(OH)2D3 or vehicle for 6 and 24h. Total RNA was extracted from the islets and the effects on global gene expression were analyzed using Affymetrix microarrays. Results and discussion: Exposure to 1,25(OH)2D3 compared to vehicle resulted in 306 and 151 differentially expressed genes after 6 and 24h, respectively (n =4, >1.3-fold, p <0.02). Of these 220 were up-regulated, whereas 86 displayed a decreased expression after 6h. Furthermore, expression levels were increased for 124 and decreased for 27 genes following 24h of exposure. Formation of intercellular junctions, cytoskeletal organization, and intracellular trafficking as well as lipid metabolism and ion transport were among the most affected gene classes. Effects on several genes already identified as being part of vitamin D signaling in other cell types were observed along with genes known to affect insulin release, although with our assay we were not able to detect any effects of 1,25(OH)2D3 on glucose-stimulated insulin release from healthy pancreatic islets. Conclusion: The effects of 1,25(OH)2D3 on the expression of cytoskeletal and intracellular trafficking genes along with genes involved in ion transport may influence insulin exocytosis. However, an effect of 1,25(OH)2D3 on insulin release could not be detected for healthy islets in contrast to islets subjected to pathological conditions such as cytokine exposure and vitamin D deficiency as suggested by other studies. Thus, in addition to previously identified tolerogenic effects on the immune system, 1,25(OH)2D3 may affect basic functions of pancreatic beta cells, with the potential to render them more resistant to the detrimental conditions encountered during type 1 and 2 diabetes. This article is part of a Special Issue entitled ‘Vitamin D Workshop’. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
20. Nonlinear MPPT techniques to control hybrid power systems.
- Author
-
Debdouche N, Benbouhenni H, Zarour L, Mehazzem F, Deffaf B, Chebabhi A, and Alghamdi TAH
- Abstract
In recent years, grid-connected multifunctional photovoltaic (PV) systems have proven to be highly efficient. This system integrates PV panels with a DC-DC boost converter (DC-DC-BC) and the electrical distribution grid (DEG). Linking the PV to the AC-DEG is accomplished through a three-level multifunctional voltage source inverter (MVSI). The DC-DC-BC component in this study is engineered to perform maximum power point tracking (MPPT) irrespective of normal or abnormal conditions. The conventional MPPT technique poses several challenges and constraints on system usage. Hence, the suggestion is to adopt synergetic control (SC) and sliding mode control (SMC) to enhance the MPPT technique's performance within the proposed system framework. Moreover, predictive direct power control is applied to the MVSI-based shunt active power filter, utilizing a phase-locked loop technique to achieve multiple objectives: minimizing energy fluctuations, injecting active power, correcting power factors, compensating reactive power, and mitigating harmonic currents. To implement the proposed system, the MATLAB is used for this purpose, with several tests used to study the behavior of the controls proposed in this work. Numerical results indicate significant reductions in active and reactive power fluctuations, with estimated rates of 38.46% and 15.30%, respectively, compared to traditional strategies. Moreover, the total harmonic distortion (THD) of the source current after filtering is reduced by 31.88% under solar irradiation of G = 1000 Wm
2 . Before filtering, the THD of current experiences a reduction estimated at 97.65%. These findings underscore the superior performance of the proposed control technique across all evaluated aspects., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
21. Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy.
- Author
-
Maunder D, Brown PM, Barron-Millar B, Lendrem DW, Naamane N, Macdonald J, Wang XN, Isaacs JD, Anderson AE, Morgan AW, Crossland RE, Mackie SL, and Pratt AG
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Treatment Outcome, Case-Control Studies, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid metabolism, Methotrexate therapeutic use, Methotrexate pharmacology, Extracellular Vesicles metabolism, Antirheumatic Agents therapeutic use, Biomarkers blood, MicroRNAs blood
- Abstract
Objectives: Extracellular vesicles (EVs) are abundant in body fluids, contributing to intercellular signalling by transferring cargo that includes microRNAs (miRs)-themselves implicated in pathobiology. For the first time we evaluated the potential of EV miRs to contribute diagnostic information in early RA, predict methotrexate (MTX) efficacy or shed light on the drug's mechanism of action., Methods: Seven hundred and ninety-eight miRs isolated from serum-derived EVs of 46 patients with untreated RA, 23 with untreated polymyalgia rheumatica (PMR; inflammatory disease control group) and 12 in whom significant inflammatory disease had been excluded (non-inflammatory controls; NICs) were profiled (NanoString); the same measurements were made for RA patients after 6 months' MTX treatment. Analyses took multiple testing into account., Results: Twenty-eight EV miRs were robustly differentially expressed between early RA (but not PMR) patients and NICs after correction for age and sex, suggesting discriminatory value. Cross-validated partial least squares-discriminant analysis also indicated the predictive potential of a distinct baseline EV miR signature with respect to MTX-induced remission at 6 months. The change in expression of 13 miRs over the course of MTX treatment differed significantly between responders and non-responders, and four of those exhibiting increased relative abundance amongst responders have known roles in regulating the pathogenic potential of synovial fibroblasts, namely miR-212-3p, miR-338-5p, miR-410-3p and miR-537., Conclusion: Our data highlight the potential of serum EV miRs as diagnostic and therapeutic biomarkers, highlighting a novel potential mechanism by which MTX may exert its therapeutic effect in early RA that warrants further investigation., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
22. Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis.
- Author
-
Brown PM, Anderson AE, Naamane N, Lendrem DW, Morgan AW, Isaacs JD, and Pratt AG
- Subjects
- Humans, CD4-Positive T-Lymphocytes metabolism, Adenosine therapeutic use, Treatment Outcome, Methotrexate therapeutic use, Biomarkers, C-Reactive Protein metabolism, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy
- Abstract
Objectives: Long-term outcomes in rheumatoid arthritis (RA) depend on early and effective disease control. Methotrexate (MTX) remains the first-line disease modifying therapy, however there are no biomarkers with which to identify those most likely to achieve remission. To address this unmet need we explored metabolic pathways involved in MTX mechanism of action within circulating CD4+T cells in a cohort of treatment naive patients with early RA., Methods: Purified CD4+T cells were isolated from peripheral blood of 68 patients with early RA commencing MTX. The expression of a range of putative MTX metabolism and mechanism of action targets were explored by flow-cytometry and transcriptional analysis. From these data significant predictors of Disease Activity Score 28-C reactive protein (DAS28-CRP) remission (<2.4 at 6 months) were determined by logistic regression (clinical; flow-cytometry data) and linear modelling (gene expression data)., Results: Low baseline DAS28-CRP was associated with remission at 6 months (p=0.02). Expression of the ectonucleotidase CD39, involved in ATP-ADP conversion during adenosine synthesis, was higher on CD4+CD25 High regulatory T cells at baseline in those achieving remission (molecules of equivalent fluorescence 1264 vs 847; p=0.007). Expression of other adenosine signalling elements in CD4+T cells were also upregulated at baseline in patients achieving remission: AMPD1 (p<0.001), ADORA2b (p=0.039) and ADORA3 (p=0.047). When combined into a single predictive metric, a combination of these variables outperformed baseline DAS28-CRP in prediction of early remission (area under the curve 0.92 vs 0.67, p=0.001) CONCLUSIONS: Adenosine signalling is important in the achievement of early remission with MTX in RA and biomarkers of adenosine activity may hold utility for the stratification of therapy in early disease., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
23. The Application of Genetic Risk Scores in Rheumatic Diseases: A Perspective.
- Author
-
Vaskimo LM, Gomon G, Naamane N, Cordell HJ, Pratt A, and Knevel R
- Subjects
- Humans, Genetic Risk Score, Risk Factors, Phenotype, Genetic Predisposition to Disease, Rheumatic Diseases genetics
- Abstract
Modest effect sizes have limited the clinical applicability of genetic associations with rheumatic diseases. Genetic risk scores (GRSs) have emerged as a promising solution to translate genetics into useful tools. In this review, we provide an overview of the recent literature on GRSs in rheumatic diseases. We describe six categories for which GRSs are used: (a) disease (outcome) prediction, (b) genetic commonalities between diseases, (c) disease differentiation, (d) interplay between genetics and environmental factors, (e) heritability and transferability, and (f) detecting causal relationships between traits. In our review of the literature, we identified current lacunas and opportunities for future work. First, the shortage of non-European genetic data restricts the application of many GRSs to European populations. Next, many GRSs are tested in settings enriched for cases that limit the transferability to real life. If intended for clinical application, GRSs are ideally tested in the relevant setting. Finally, there is much to elucidate regarding the co-occurrence of clinical traits to identify shared causal paths and elucidate relationships between the diseases. GRSs are useful instruments for this. Overall, the ever-continuing research on GRSs gives a hopeful outlook into the future of GRSs and indicates significant progress in their potential applications.
- Published
- 2023
- Full Text
- View/download PDF
24. Characterization of age-associated B cells in early drug-naïve rheumatoid arthritis patients.
- Author
-
Vidal-Pedrola G, Naamane N, Cameron JA, Pratt AG, Mellor AL, Isaacs JD, Scheel-Toellner D, and Anderson AE
- Subjects
- Humans, Synovial Fluid metabolism, HLA-DR Antigens metabolism, Receptors, Chemokine metabolism, Arthritis, Rheumatoid, Arthritis, Psoriatic
- Abstract
Age-associated B cells (ABCs) are an immune cell subset linked to autoimmunity, infection and ageing, and whose pathophysiological importance was recently highlighted using single cell synovial tissue profiling. To elucidate their pathophysiological relevance, peripheral blood (PB) ABCs from early rheumatoid arthritis (eRA) patients naïve to disease-modifying anti-rheumatic drugs (DMARDs) were compared with their synovial fluid (SF) counterparts, and to PB ABCs from psoriatic arthritis patients and healthy controls. PB and SF B-cell subsets were phenotyped by multi-parameter flow cytometry, sorted and subjected to gene expression profiling (NanoString nCounter® Immunology V2 Panel) and functional characterization (stimulated cytokine measurements by immunoassay). PB ABCs of eRA patients, which are transcriptionally distinct from those of control cohorts, express chemokine receptors and adhesion molecules, such as CXCR3, that favour homing to inflammatory sites over lymphoid tissue. These cells are an activated, class-switched B-cell subset expressing high levels of HLA-DR, co-stimulatory molecules and T-bet. Their secretion profile includes IL-12p70 and IL-23 but low levels of IL-10. High surface expression of FcRL family members, including FcRL3, furthermore suggests a role for these cells in autoimmunity. Finally, and unlike in the periphery where they are rare, ABCs are the predominant B-cell subsets in SF. These observations indicate the predilection of ABCs for inflammatory tissue in RA, where their propensity for antigen presentation and pro-inflammatory phenotype may support autoimmune pathology. Their potential as a therapeutic target therefore warrants further study., (© 2022 The Authors. Immunology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
25. Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
- Author
-
Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG, and Isaacs JD
- Abstract
Objectives: An interferon (IFN) gene signature (IGS) is present in approximately 50% of early, treatment naive rheumatoid arthritis (eRA) patients where it has been shown to negatively impact initial response to treatment. We wished to validate this effect and explore potential mechanisms of action., Methods: In a multicentre inception cohort of eRA patients (n=191), we examined the whole blood IGS ( MxA, IFI44L, OAS1, IFI6, ISG15 ) with reference to circulating IFN proteins, clinical outcomes and epigenetic influences on circulating CD19+ B and CD4+ T lymphocytes., Results: We reproduced our previous findings demonstrating a raised baseline IGS. We additionally showed, for the first time, that the IGS in eRA reflects circulating IFN-α protein. Paired longitudinal analysis demonstrated a significant reduction between baseline and 6-month IGS and IFN-α levels (p<0.0001 for both). Despite this fall, a raised baseline IGS predicted worse 6-month clinical outcomes such as increased disease activity score (DAS-28, p=0.025) and lower likelihood of a good EULAR clinical response (p=0.034), which was independent of other conventional predictors of disease activity and clinical response. Molecular analysis of CD4+ T cells and CD19+ B cells demonstrated differentially methylated CPG sites and dysregulated expression of disease relevant genes, including PARP9, STAT1, and EPSTI1 , associated with baseline IGS/IFNα levels. Differentially methylated CPG sites implicated altered transcription factor binding in B cells (GATA3, ETSI, NFATC2, EZH2) and T cells (p300, HIF1α)., Conclusions: Our data suggest that, in eRA, IFN-α can cause a sustained, epigenetically mediated, pathogenic increase in lymphocyte activation and proliferation, and that the IGS is, therefore, a robust prognostic biomarker. Its persistent harmful effects provide a rationale for the initial therapeutic targeting of IFN-α in selected patients with eRA., Competing Interests: Competing interests: JDI discloses research grants from Pfizer, Janssen and GSK; conference support from Eli Lilly and Gilead; speaker/consulting fees from AbbVie, BMS, Gilead, Roche and UCB. FAHC discloses speaker fees from AstraZeneca.The remaining authors have no competing interests., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
26. A Bayesian network approach incorporating imputation of missing data enables exploratory analysis of complex causal biological relationships.
- Author
-
Howey R, Clark AD, Naamane N, Reynard LN, Pratt AG, and Cordell HJ
- Subjects
- Algorithms, Humans, Bayes Theorem, Data Interpretation, Statistical
- Abstract
Bayesian networks can be used to identify possible causal relationships between variables based on their conditional dependencies and independencies, which can be particularly useful in complex biological scenarios with many measured variables. Here we propose two improvements to an existing method for Bayesian network analysis, designed to increase the power to detect potential causal relationships between variables (including potentially a mixture of both discrete and continuous variables). Our first improvement relates to the treatment of missing data. When there is missing data, the standard approach is to remove every individual with any missing data before performing analysis. This can be wasteful and undesirable when there are many individuals with missing data, perhaps with only one or a few variables missing. This motivates the use of imputation. We present a new imputation method that uses a version of nearest neighbour imputation, whereby missing data from one individual is replaced with data from another individual, their nearest neighbour. For each individual with missing data, the subsets of variables to be used to select the nearest neighbour are chosen by sampling without replacement the complete data and estimating a best fit Bayesian network. We show that this approach leads to marked improvements in the recall and precision of directed edges in the final network identified, and we illustrate the approach through application to data from a recent study investigating the causal relationship between methylation and gene expression in early inflammatory arthritis patients. We also describe a second improvement in the form of a pseudo-Bayesian approach for upweighting certain network edges, which can be useful when there is prior evidence concerning their directions., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
27. Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.
- Author
-
Moussa Agha D, Rouas R, Najar M, Bouhtit F, Naamane N, Fayyad-Kazan H, Bron D, Meuleman N, Lewalle P, and Merimi M
- Subjects
- Biomarkers, Tumor metabolism, Bone Marrow pathology, Female, Humans, Male, Middle Aged, Prognosis, Bone Marrow metabolism, Circulating MicroRNA metabolism, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute therapy, Tumor Microenvironment
- Abstract
Background: In addition to their roles in different biological processes, microRNAs in the tumor microenvironment appear to be potential diagnostic and prognostic biomarkers for various malignant diseases, including acute myeloid leukemia (AML). To date, no screening of circulating miRNAs has been carried out in the bone marrow compartment of AML. Accordingly, we investigated the circulating miRNA profile in AML bone marrow at diagnosis (AMLD) and first complete remission post treatment (AMLPT) in comparison to healthy donors (HD)., Methods: Circulating miRNAs were isolated from AML bone marrow aspirations, and a low-density TaqMan miRNA array was performed to identify deregulated miRNAs followed by quantitative RT-PCR to validate the results. Bioinformatic analysis was conducted to evaluate the diagnostic and prognostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s)., Results: We found several deregulated miRNAs between the AMLD vs. HD vs. AMLPT groups, which were involved in tumor progression and immune suppression pathways. We also identified significant diagnostic and prognostic signatures with the ability to predict AML patient treatment response., Conclusions: This study provides a possible role of enriched circulating bone marrow miRNAs in the initiation and progression of AML and highlights new markers for prognosis and treatment monitoring.
- Published
- 2020
- Full Text
- View/download PDF
28. Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci.
- Author
-
Clark AD, Nair N, Anderson AE, Thalayasingam N, Naamane N, Skelton AJ, Diboll J, Barton A, Eyre S, Isaacs JD, Pratt AG, and Reynard LN
- Subjects
- Aged, Arthritis, Rheumatoid immunology, Female, Genetic Loci, Genotype, Humans, Male, Middle Aged, Arthritis, Rheumatoid genetics, B-Lymphocytes, CD4-Positive T-Lymphocytes, DNA Methylation, Genetic Predisposition to Disease
- Abstract
Background: Defining regulatory mechanisms through which noncoding risk variants influence the cell-mediated pathogenesis of immune-mediated disease (IMD) has emerged as a priority in the post-genome-wide association study era., Objectives: With a focus on rheumatoid arthritis, we sought new insight into genetic mechanisms of adaptive immune dysregulation to help prioritize molecular pathways for targeting in this and related immune pathologies., Methods: Whole-genome methylation and transcriptional data from isolated CD4
+ T cells and B cells of more than 100 genotyped and phenotyped patients with inflammatory arthritis, all of whom were naive to immunomodulatory treatments, were obtained. Analysis integrated these comprehensive data with genome-wide association study findings across IMDs and other publicly available resources., Results: We provide strong evidence that disease-associated DNA variants regulate cis-CpG methylation in CD4+ T and/or B cells at 37% RA loci. Using paired, cell-specific transcriptomic data and causal inference testing, we identify examples where site-specific DNA methylation in turn mediates gene expression, including FCRL3 in both cell types and ORMDL3/GSDMB, IL6ST/ANKRD55, and JAZF1 in CD4+ T cells. A number of genes regulated in this way highlight mechanisms common to RA and other IMDs including multiple sclerosis and asthma, in turn distinguishing them from osteoarthritis, a primarily degenerative disease. Finally, we corroborate the observed effects experimentally., Conclusions: Our observations highlight important mechanisms of genetic risk in RA and the wider context of immune dysregulation. They confirm the utility of DNA methylation profiling as a tool for causal gene prioritization and, potentially, therapeutic targeting in complex IMD., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
29. Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic.
- Author
-
Lendrem BC, Lendrem DW, Pratt AG, Naamane N, McMeekin P, Ng WF, Allen AJ, Power M, and Isaacs JD
- Subjects
- Humans, Prevalence, ROC Curve, Biological Assay methods, Biomarkers analysis, Diagnostic Tests, Routine methods
- Abstract
The Receiver Operating Characteristic (ROC) curve and the Area Under the Curve (AUC) of the ROC curve are widely used in discovery to compare the performance of diagnostic and prognostic assays. The ROC curve has the advantage that it is independent of disease prevalence. However, in this note, we remind scientists and clinicians that the performance of an assay upon translation to the clinic is critically dependent upon that very same prevalence. Without an understanding of prevalence in the test population, even robust bioassays with excellent ROC characteristics may perform poorly in the clinic. While the exact prevalence in the target population is not always known, simple plots of candidate assay performance as a function of prevalence rate give a better understanding of the likely real-world performance and a greater understanding of the likely impact of variation in that prevalence on translation to the clinic., (© 2019 John Wiley & Sons, Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
30. IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function.
- Author
-
Ridgley LA, Anderson AE, Maney NJ, Naamane N, Skelton AJ, Lawson CA, Emery P, Isaacs JD, Carmody RJ, and Pratt AG
- Subjects
- Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid pathology, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell immunology, STAT3 Transcription Factor immunology, Arthritis, Rheumatoid immunology, CD4-Positive T-Lymphocytes immunology, Interleukin-6 immunology, Models, Immunological, Signal Transduction immunology, Transcription, Genetic immunology
- Abstract
Objective: We have previously shown that increased circulating interleukin-6 (IL-6) results in enhanced CD4+ T cell signaling via signal transduction and activator of transcription-3 (STAT3) in early rheumatoid arthritis (RA). We tested the hypothesis that transcriptional "imprinting" of T-cells by this mechanism skews downstream effector responses, reinforcing immune dysregulation at a critical, but targetable, disease phase. Methods: We modeled naïve CD4+ T cell exposure to pathophysiological concentrations of IL-6 in vitro , assessing the dynamic transcriptional and functional consequences for downstream effector cells utilizing microarray and flow cytometry. Fresh blood from treatment-naïve early arthritis patients was phenotyped in parallel for comparison. Results: T cell sensitivity to IL-6 was most marked in the naïve subset, and related to gp130 rather than IL-6R expression. Exposure of healthy naïve CD4+ T cells to IL-6 induced the same STAT3 target genes as previously seen to discriminate RA patients from disease controls. After TCR stimulation IL-6 pre-exposed cells exhibited enhanced proliferative capacity, activation, and a propensity toward Th1 differentiation, compared to non-exposed cells. An entirely analogous phenotype was observed in early RA compared to control CD4+ T cells. Conclusions: Sustained IL-6 exposure at a critical point in the natural history of RA "primes" the adaptive immune system to respond aberrantly to TCR stimulation, potentiating disease induction with implications for the optimal timing of targeted therapy.
- Published
- 2019
- Full Text
- View/download PDF
31. STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and islet inflammation.
- Author
-
Moore F, Naamane N, Colli ML, Bouckenooghe T, Ortis F, Gurzov EN, Igoillo-Esteve M, Mathieu C, Bontempi G, Thykjaer T, Ørntoft TF, and Eizirik DL
- Subjects
- Animals, Apoptosis drug effects, Apoptosis Regulatory Proteins genetics, Apoptosis Regulatory Proteins immunology, Cell Differentiation immunology, Cells, Cultured, Feedback, Physiological physiology, Gene Knockdown Techniques, Interferon Regulatory Factor-1 immunology, Interferon Regulatory Factor-1 metabolism, Interferon-gamma immunology, Interferon-gamma metabolism, Interleukin-1beta pharmacology, Male, Neuropeptides genetics, Neuropeptides immunology, RNA, Small Interfering, Rats, Rats, Wistar, STAT1 Transcription Factor genetics, STAT1 Transcription Factor metabolism, Transcription, Genetic immunology, Apoptosis immunology, Insulin-Secreting Cells immunology, Insulin-Secreting Cells pathology, Pancreatitis immunology, Pancreatitis pathology, STAT1 Transcription Factor immunology
- Abstract
Cytokines produced by islet-infiltrating immune cells induce β-cell apoptosis in type 1 diabetes. The IFN-γ-regulated transcription factors STAT1/IRF-1 have apparently divergent effects on β-cells. Thus, STAT1 promotes apoptosis and inflammation, whereas IRF-1 down-regulates inflammatory mediators. To understand the molecular basis for these differential outcomes within a single signal transduction pathway, we presently characterized the gene networks regulated by STAT1 and IRF-1 in β-cells. This was done by using siRNA approaches coupled to microarray analysis of insulin-producing cells exposed or not to IL-1β and IFN-γ. Relevant microarray findings were further studied in INS-1E cells and primary rat β-cells. STAT1, but not IRF-1, mediates the cytokine-induced loss of the differentiated β-cell phenotype, as indicated by decreased insulin, Pdx1, MafA, and Glut2. Furthermore, STAT1 regulates cytokine-induced apoptosis via up-regulation of the proapoptotic protein DP5. STAT1 and IRF-1 have opposite effects on cytokine-induced chemokine production, with IRF-1 exerting negative feedback inhibition on STAT1 and downstream chemokine expression. The present study elucidates the transcriptional networks through which the IFN-γ/STAT1/IRF-1 axis controls β-cell function/differentiation, demise, and islet inflammation.
- Published
- 2011
- Full Text
- View/download PDF
32. In silico identification of NF-kappaB-regulated genes in pancreatic beta-cells.
- Author
-
Naamane N, van Helden J, and Eizirik DL
- Subjects
- Algorithms, Animals, Discriminant Analysis, Humans, Mice, Oligonucleotide Array Sequence Analysis methods, Pan troglodytes, Rats, Cytokines metabolism, Gene Expression Profiling methods, Gene Expression Regulation physiology, Insulin-Secreting Cells metabolism, Models, Biological, NF-kappa B metabolism, Signal Transduction physiology
- Abstract
Background: Pancreatic beta-cells are the target of an autoimmune attack in type 1 diabetes mellitus (T1DM). This is mediated in part by cytokines, such as interleukin (IL)-1beta and interferon (IFN)-gamma. These cytokines modify the expression of hundreds of genes, leading to beta-cell dysfunction and death by apoptosis. Several of these cytokine-induced genes are potentially regulated by the IL-1beta-activated transcription factor (TF) nuclear factor (NF)-kappaB, and previous studies by our group have shown that cytokine-induced NF-kappaB activation is pro-apoptotic in beta-cells. To identify NF-kappaB-regulated gene networks in beta-cells we presently used a discriminant analysis-based approach to predict NF-kappaB responding genes on the basis of putative regulatory elements., Results: The performance of linear and quadratic discriminant analysis (LDA, QDA) in identifying NF-kappaB-responding genes was examined on a dataset of 240 positive and negative examples of NF-kappaB regulation, using stratified cross-validation with an internal leave-one-out cross-validation (LOOCV) loop for automated feature selection and noise reduction. LDA performed slightly better than QDA, achieving 61% sensitivity, 91% specificity and 87% positive predictive value, and allowing the identification of 231, 251 and 580 NF-kappaB putative target genes in insulin-producing INS-1E cells, primary rat beta-cells and human pancreatic islets, respectively. Predicted NF-kappaB targets had a significant enrichment in genes regulated by cytokines (IL-1beta or IL-1beta + IFN-gamma) and double stranded RNA (dsRNA), as compared to genes not regulated by these NF-kappaB-dependent stimuli. We increased the confidence of the predictions by selecting only evolutionary stable genes, i.e. genes with homologs predicted as NF-kappaB targets in rat, mouse, human and chimpanzee., Conclusion: The present in silico analysis allowed us to identify novel regulatory targets of NF-kappaB using a supervised classification method based on putative binding motifs. This provides new insights into the gene networks regulating cytokine-induced beta-cell dysfunction and death.
- Published
- 2007
- Full Text
- View/download PDF
33. New approaches for in silico identification of cytokine-modified beta cell gene networks.
- Author
-
Kutlu B, Naamane N, Berthou L, and Eizirik DL
- Subjects
- Animals, Apoptosis, Binding Sites, Computational Biology, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 physiopathology, Humans, Interferon-gamma pharmacology, Interleukin-1 pharmacology, Islets of Langerhans physiopathology, Kinetics, NF-kappa B antagonists & inhibitors, NF-kappa B pharmacology, Nitric Oxide metabolism, Oligonucleotide Array Sequence Analysis, RNA, Messenger genetics, Cytokines pharmacology, Gene Expression Regulation drug effects, Islets of Langerhans metabolism, Microarray Analysis, NF-kappa B metabolism
- Abstract
Beta cell dysfunction and death in type 1 diabetes mellitus (T1DM) is caused by direct contact with activated macrophages and T lymphocytes and by exposure to soluble mediators secreted by these cells, such as cytokines and nitric oxide. Cytokine-induced apoptosis depends on the expression of pro- and anti-apoptotic genes that remain to be characterized. Using microarray analyses, we identified several transcription factor and "effector" gene networks regulated by interleukin-1beta and/or interferon-gamma in beta cells. This suggests that beta cell fate following exposure to cytokines is a complex and highly regulated process, depending on the duration and severity of perturbation of key gene networks. In order to draw correct conclusions from these massive amounts of data, we need to utilize novel bioinformatics and statistical tools. Thus, we are presently performing in silico analysis for the localization of binding sites for the transcription factor NF-kappaB (previously shown to be pivotal for beta cell apoptosis) in 15 temporally related gene clusters, identified by time-course microarray analysis. In silico analysis is based on a broad range of computational techniques used to detect motifs in a DNA sequence corresponding to the binding site of a transcription factor. These computer-based findings must be validated by use of positive and negative controls, and by "ChIP on chip" analysis. Moreover, new statistical approaches are required to decrease false positive findings. These novel approaches will constitute a "proof of principle" for the integrated use of bioinformatics and functional genomics in the characterization of relevant cytokine-regulated beta cell gene networks leading to beta cell apoptosis in T1DM.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.